MHC class II proteins and disease: A structural perspective

Nature Reviews Immunology

Volumn 6, Issue 4, 2006, Pages 271-282

  Jones, E Yvonne ^a   Fugger, Lars ^a,b   Strominger, Jack L ^c   Siebold, Christian ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTEN; HEMAGGLUTININ; HLA DQ1 ANTIGEN; HLA DQ2 ANTIGEN; HLA DR ANTIGEN; INSULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN BASIC PROTEIN; OREXIN; T LYMPHOCYTE RECEPTOR;

ALLELE; ALLERGIC ENCEPHALOMYELITIS; AMINO TERMINAL SEQUENCE; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELIAC DISEASE; CRYSTAL STRUCTURE; DATA BASE; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC RISK; GENETICS; HELPER CELL; HUMAN; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; NARCOLEPSY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

AUTOIMMUNE DISEASES; BINDING SITES; EPITOPES, T-LYMPHOCYTE; HLA-D ANTIGENS; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 33645290018     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1805     Document Type: Review

References (73)

1. Brown, J. H. et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364, 33-39 (1993). The classic analysis of an MHC class II molecule in complex with a single peptide. This structure detailed the fundamental characteristics of the peptide-binding groove.
2. Stern, L. J. et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215-221 (1994).
3. Schueler-Furman, O., Altuvia, Y. & Margalit, H. Examination of possible structural constraints of MHC-binding peptides by assessment of their native structure within their source proteins. Proteins 45, 47-54 (2001).
4. Li, Y., Li, H., Martin, R. & Mariuzza, R. A. Structural basis for the binding of an immunodominant peptide from myelin basic protein in different registers by two HLA-DR2 proteins. J. Mol. Biol. 304, 177-188 (2000). This paper reports the crystal structure of HLA-DR2a in complex with an immunodominant epitope from MBR Together with reference 5, the structure illustrates how the same peptide can be bound in different conformations by different MHC class II molecules.
5. Smith, K. J., Pyrdol, J., Gauthier, L., Wiley, D. C. & Wucherpfennig, K. W. Crystal structure of HLA-DR2 (DRA*0101, DRBI*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 188, 1511-1520 (1998). This paper reports the crystal structure of HLA-DR2b in complex with the multiple-sclerosis-associated immunodominant epitope from MBP described in reference 4. When presented in the context of HLA-DR2b, this epitope is known to elicit disease-causing T-cell responses.
6. Okun, M. L., Lin, L., Pelin, Z., Hong, S. & Mignot, E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 25, 27-35 (2002).
7. Mignot, E. Genetic and familial aspects of narcolepsy. Neurology 50, S16-S22 (1998).
8. Matsuki, K. et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 339, 1052 (1992).
9. Mignot, E. et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am. J. Hum. Genet. 68, 686-699 (2001).
10. Taheri, S., Zeitzer, J. M. & Mignot, E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu. Rev. Neurosci. 25, 283-313 (2002).
11. Nishino, S., Ripley, B., Overeem, S., Lammers, G. J. & Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39-40 (2000).
12. Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Med. 6, 991-997 (2000).
13. Siebold, C. et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc. Natl Acad. Sci. USA 101, 1999-2004 (2004). This structural analysis of HLA-DQ6.2 reveals features of the peptide-binding groove that correlate with susceptibility to narcolepsy and protection against type 1 diabetes.
14. Farrell, R. J. & Kelly, C. P. Celiac sprue. N. Engl. J. Med. 346, 180-188 (2002).
15. Sollid, L. M. et al. Evidence for a primary association of celiac disease to a particular HLA-DQ α/β heterodimer. J. Exp. Med. 169, 345-350 (1989).
16. Lundin, K. E., Scott, H., Fausa, O., Thorsby, E. & Sollid, L. M. T cells from the small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac disease patient preferentially recognize gliadin when presented by DQ8. Hum. Immunol. 41, 285-291 (1994).
17. Lundin, K. E. et al. Gliadin-specific, HLA-DQ(α1*0501, β1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J. Exp. Med. 178, 187-196 (1993).
18. van de Wal, Y. et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J. Immunol. 161, 1585-1588 (1998).
19. Molberg, O. et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nature Med. 4, 713-717 (1998).
20. Kim, C. Y., Quarsten, H., Bergseng, E., Khosla, C. & Sollid, L. M. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc. Natl Acad. Sci. USA 101, 4175-4179 (2004). The structure of HLA-DQ2 in complex with a gluten-derived peptide shows how MHC class II peptide-binding-groove characteristics allow the binding of peptides from atypical protein sequences, in this case gliadin, leading to susceptibility to coeliac disease.
21. g7 molecules show common sequence specificity. J. Clin. Invest. 115, 2268-2276 (2005).
22. Atkinson, M. A. & Eisenbarth, G. S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358, 221-229 (2001).
23. Kent, S. C. et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 435, 224-228 (2005).
24. Todd, J. A., Bell, J. I. & McDevitt, H. O. HLA-DQ β gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329, 599-604 (1987). The classic analysis demonstrating that MHC class II polymorphisms can be linked to an autoimmune disease.
25. Todd, J. A. & Wicker, L. S. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity 15, 387-395 (2001).
26. Baisch, J. M. et al. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. N. Engl. J. Med. 322, 1836-1841 (1990).
27. Cucca, F. et al. A correlation between the relative predisposition of MHC class II alleles to type 1 diabetes and the structure of their proteins. Hum. Mol. Genet 10, 2025-2037 (2001).
28. Tisch, R. & McDevitt, H. Insulin-dependent diabetes mellitus. Cell 85, 291-297 (1996).
29. Robinson, C. P. et al. A novel NOD-derived murine model of primary Sjogren's syndrome. Arthritis Rheum. 41, 150-156 (1998).
30. Lee, K. H., Wucherpfennig, K. W. & Wiley, D. C. Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nature Immunol. 2, 501-507 (2001). This paper provided the first structural analysis of an HLA-DQ molecule, HLA-DQ8. The structure was of HLA-DQ8 in complex with a peptide derived from human insulin (a candidate autoantigen in type 1 diabetes).
31. Latek, R. R. et al. Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Immunity 12,699-710 (2000).
32. g7 and autoimmune diabetes. Science 288, 505-511 (2000).
33. Fremont, D. H., Hendrickson, W. A., Marrack, P. & Kappler, J. Structures of an MHC class II molecule with covalently bound single peptides. Science 272, 1001-1004 (1996).
34. Yamagata, K. et al. Aspartic acid at position 57 of DQ β chain does not protect against type 1 (insulin-dependent) diabetes mellitus in Japanese subjects. Diabetologia 32, 762-764 (1989).
35. Awata, T., Kuzuya, T., Matsuda, A., Iwamoto, Y. & Kanazawa, Y. Genetic analysis of HLA class II alleles and susceptibility to type 1 (insulin-dependent) diabetes mellitus in Japanese subjects. Diabetologia 35, 419-424 (1992).
36. Zhu, Y., Rudensky, A. Y., Corper, A. L., Teyton, L. & Wilson, I. A. Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif. J. Mol. Biol. 326, 1157-1174 (2003).
37. Ettinger, R. A. & Kwok, W. W. A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. J. Immunol. 160, 2365-2373 (1998).
38. Qiao, S. W. et al. Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: importance of proline spacing and glutamine deamidation. J. Immunol. 175, 254-261 (2005).
39. Arentz-Hansen, H. et al. The intestinal T cell response to α-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J. Exp. Med. 191, 603-612 (2000).
40. Lee, D. M. & Weinblatt, M. E. Rheumatoid arthritis. Lancet 358, 903-911 (2001).
41. Stastny, P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N. Engl. J. Med. 298, 869-871 (1978).
42. Wordsworth, B. P. et al. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc. Natl Acad. Sci. USA 86, 10049-10053 (1989).
43. Gregersen, P. K., Silver, J. & Winchester, R. J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205-1213 (1987).
44. Hammer, J. et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J. Exp. Med. 181, 1847-1855 (1995).
45. Van Boxel, J. A. & Paget, S. A. Predominantly T-cell infiltrate in rheumatoid synovial membranes. N. Engl. J. Med. 293, 517-520 (1975).
46. Andersson, E. C. et al. Definition of MHC and T cell receptor contacts in the HLA-DR4-restricted immunodominant epitope in type II collagen and characterization of collagen-induced arthritis in HLA-DR4 and human CD4 transgenic mice. Proc. Natl Acad. Sci. USA 95, 7574-7579 (1998).
47. Rosloniec, E. F. et al. An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen. J. Exp. Med. 185, 1113-1122 (1997).
48. Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003).
49. Fugger, L., Rothbard, J. B. & Sonderstrup-McDevitt, G. Specificity of an HLA-DRB1*0401-restricted T cell response to type II collagen. Eur. J. Immunol. 26, 928-933 (1996).
50. Svendsen, P. et al. Tracking of proinflammatory collagen-specific T cells in early and late collagen-induced arthritis in humanized mice. J. Immunol. 173, 7037-7045 (2004).
51. Latham, K. A., Whittington, K. B., Zhou, R., Qian, Z. & Rosloniec, E. F. Ex vivo characterization of the autoimmune T cell response in the HLA-DR1 mouse model of collagen-induced arthritis reveals long-term activation of type II collagen-specific cells and their presence in arthritic joints. J. Immunol. 174, 3978-3985 (2005).
52. Dessen, A., Lawrence, C. M., Cupo, S., Zaller, D. M. & Wiley, D. C. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 7, 473-481 (1997). The structural analysis of the rheumatoid-arthritis-associated molecule HLA-DR4 revealed a peptide-binding groove that is well suited to binding the glycine-rich peptides derived from type II collagen. The structure showed that a sequence common to all the main rheumatoid-arthritis-associated MHC class II molecules allows negatively charged P4 residues to be accommodated.
53. Hill, J. A. et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol. 171, 538-541 (2003).
54. Marshall, K. et al. Prediction of peptide affinity to HLA-DRB1*0401. J. Immunol. 154, 5927-5933 (1995).
55. Hennecke, J. & Wiley, D. C. Structure of a complex of the human α/β T cell receptor (TCR) HA 1.7, influenza hemagglutinin peptide, and major histocompatibility complex class II molecule, HLA-DR4 (DRA*0101 and DRB1*0401): insight into TCR cross-restriction and alloreactivity. J. Exp. Med. 195, 571-581 (2002).
56. Hammer, J., Takacs, B. & Sinigaglia, F. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J. Exp. Med. 176, 1007-1013 (1992).
57. Wucherpfennig, K. W. et al. Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc. Natl Acad. Sci. USA 92, 11935-11939 (1995).
58. Keegan, B. M. & Noseworthy, J. H. Multiple sclerosis. Annu. Rev. Med. 53, 285-302 (2002).
59. Fogdell, A., Hillert, J., Sachs, C. & Olerup, O. The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele. Tissue Antigens 46, 333-336 (1995).
60. Oksenberg, J. R. et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am. J. Hum. Genet. 74, 160-167 (2004).
61. Sospedra, M. & Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683-747 (2005).
62. β gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362, 68-70 (1993).
63. Krogsgaard, M. et al. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 191, 1395-1412 (2000).
64. Madsen, L. S. et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nature Genet 23, 343-347 (1999).
65. Lang, H. L. et al. A functional and structural basis for TCR crossreactivity in multiple sclerosis. Nature Immunol. 3, 940-943 (2002). The structure of HLA-DR2a, in complex with a peptide derived from EBV, was compared with the structure of HLA-DR2b in complex with the immunodominant epitope from MBP, revealing a clear example of molecular mimicry. These complexes stimulate crossreactive T cells.
66. Wucherpfennig, K. W. et al. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179, 279-290 (1994).
67. Vogt, A. B. et al. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J. Immunol. 153, 1665-1673 (1994).
68. Hahn, M., Nicholson, M. J., Pyrdol, J. & Wucherpfennig, K. W. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nature Immunol. 6, 490-496 (2005).
69. Li, Y. et al. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J. 24, 2968-2979 (2005).
70. Maynard, J. et al. Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: insights into MHC bias and antigen specificity. Immunity 22, 81-92 (2005).
71. Bornstein, M. B. et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N. Engl. J. Med. 317, 408-414 (1987).
72. Stern, J. N. et al. Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 102, 1620-1625 (2005).
73. Stuart, D. I., Levine, M., Muirhead, H. & Stammers, D. K. Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 Å. J. Mol. Biol. 134, 109-142 (1979).